Press releaseBusiness Wire
Gossamer Bio
GOSS · NASDAQ
$9.58+$1.15 (+13.64%)TodayMarket closed ·
Prev close $8.43
Latest news
- Press releaseBusiness Wire
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
- Press releaseBusiness Wire
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
- Press releaseBusiness Wire
Gossamer Bio Announces 1-for-80 Reverse Stock Split
- Press releaseBusiness Wire
Gossamer Bio to Present at Cantor Global Healthcare Conference
- NewsAkanksha Bakshi
Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
- Press releaseBusiness Wire
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsVandana Singh
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate
- News
Gossamer Bio Secures Stockholders Approval For Proposals Related To Convertible Note Exchange And Reverse Stock Split; Reports $57M Cash Position
- News
Gossamer Bio Advances Seralutinib Toward NDA In September 2026, Reacquires Global Rights To Seralutinib From Chiesi
- Press releaseBusiness Wire
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
- Press releaseBusiness Wire
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
- Press releaseBusiness Wire
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- Press releaseBusiness Wire
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- Press releaseBusiness Wire
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- Press releaseBusiness Wire
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline
- Press releaseBusiness Wire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
- Press releaseGlobe Newswire
GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
- Press releasePRNewswire
GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
- Press releaseGlobe Newswire
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st
- Press releaseBusiness Wire
Deadline Soon: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
- Press releasePRNewswire
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
- Press releaseGlobe Newswire
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026 - GOSS
- Press releasePRNewswire
Gossamer Bio Deadline: GOSS Investors with Losses in Excess of $100K Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
- Press releasePRNewswire
GOSS 4-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
- Press releaseGlobe Newswire
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
- Press releasePRNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releaseGlobe Newswire
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Pinterest, Inc. (PINS), New Era Energy & Digital, Inc. (NUAI), and Gossamer Bio, Inc. (GOSS) Announced by Holzer & Holzer, LLC
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseBusiness Wire
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
- Press releasePRNewswire
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
- Press releaseGlobe Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
- NewsAvi Kapoor
Dow Tumbles Over 700 Points; Dominion Energy Posts Upbeat Earnings
- NewsAvi Kapoor
US Stocks Mixed; Domino's Pizza Shares Gain After Q4 Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.